{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:14:38Z","timestamp":1790000078691,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejca.2024.115098","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T05:46:47Z","timestamp":1730094407000},"page":"115098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Liquid biopsy with plasma Epstein-Barr virus DNA characterizes biological relapse for the prediction of cancer recurrence in non-disseminated nasopharyngeal carcinoma"],"prefix":"10.1016","volume":"213","author":[{"given":"Qixian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjiao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaosu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueguan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10192","key":"10.1016\/j.ejca.2024.115098_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejca.2024.115098_bib2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.ejca.2024.115098_bib3","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2024.115098_bib4","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jama.2022.13997","article-title":"Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma: a randomized clinical trial","volume":"328","author":"Tang","year":"2022","journal-title":"Jama"},{"issue":"9","key":"10.1016\/j.ejca.2024.115098_bib5","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hed.24451","article-title":"Relapse status as a prognostic factor in patients receiving salvage surgery for recurrent or residual nasopharyngeal cancer after definitive treatment","volume":"38","author":"Chee","year":"2016","journal-title":"Head Neck"},{"issue":"3","key":"10.1016\/j.ejca.2024.115098_bib6","first-page":"1046","article-title":"Epstein-Barr virus DNA in serum\/plasma as a tumor marker for nasopharyngeal cancer","volume":"6","author":"Shotelersuk","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2024.115098_bib7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1701717","article-title":"Analysis of plasma Epstein-Barr Virus DNA to screen for nasopharyngeal cancer","volume":"377","author":"Chan","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2024.115098_bib8","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1158\/1078-0432.CCR-09-2796","article-title":"Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic\/recurrent nasopharyngeal carcinoma","volume":"16","author":"Wang","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2024.115098_bib9","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1038\/s41467-019-11853-y","article-title":"Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma","volume":"10","author":"Lv","year":"2019","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.ejca.2024.115098_bib10","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1200\/JCO.2004.05.178","article-title":"Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA","volume":"22","author":"Chan","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.115098_bib11","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.18632\/oncotarget.14137","article-title":"Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/j.ejca.2024.115098_bib12","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2024.115098_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/v15010066","article-title":"The dynamic change in plasma epstein-barr virus dna load over a long-term follow-up period predicts prognosis in nasopharyngeal carcinoma","volume":"15","author":"Gihbid","year":"2022","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.ejca.2024.115098_bib14","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/cncr.32770","article-title":"Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma","volume":"126","author":"Chen","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.115098_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106655","article-title":"Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma","volume":"148","author":"Neo","year":"2024","journal-title":"Oral Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2024.115098_bib16","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S1470-2045(22)00505-8","article-title":"International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic","volume":"23","author":"Lee","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.115098_bib17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.ejca.2024.115098_bib18","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1200\/JCO.2005.04.0756","article-title":"Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition","volume":"24","author":"Stephenson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115098_bib19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/1471-2407-12-208","article-title":"Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population","volume":"12","author":"Ferrari","year":"2012","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2024.115098_bib20","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/cncr.20129","article-title":"Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA","volume":"100","author":"Hong","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.115098_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejca.2021.05.022","article-title":"A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma","volume":"153","author":"Lee","year":"2021","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2024.115098_bib22","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-20-3519","article-title":"Dynamic changes of post-radiotherapy plasma epstein-barr virus DNA in a randomized trial of adjuvant chemotherapy versus observation in nasopharyngeal cancer","volume":"27","author":"Hui","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2024.115098_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10555-023-10096-0","article-title":"Tumor dormancy and disease recurrence","volume":"42","author":"Kirkland","year":"2023","journal-title":"Cancer Metastas-- Rev"},{"issue":"3","key":"10.1016\/j.ejca.2024.115098_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/cam4.3669","article-title":"Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma","volume":"10","author":"Li","year":"2021","journal-title":"Cancer Med"},{"issue":"19","key":"10.1016\/j.ejca.2024.115098_bib25","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1002\/cncr.26069","article-title":"Plasma Epstein-Barr virus DNA screening followed by \u00b9\u2078F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma","volume":"117","author":"Wang","year":"2011","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2024.115098_bib26","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.annonc.2020.03.289","article-title":"Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy","volume":"31","author":"Hui","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.115098_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110032","article-title":"Oral chemotherapy versus observation alone in nasopharyngeal carcinoma patients with persistently detected circulating cell-free Epstein-Barr virus DNA during follow-up","volume":"190","author":"Huang","year":"2024","journal-title":"Radio Oncol"},{"key":"10.1016\/j.ejca.2024.115098_bib28","article-title":"Analysis of plasma epstein-barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial","author":"Chan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115098_bib29","article-title":"Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes","volume":"11","author":"Kim","year":"2020","journal-title":"Front Immunol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T08:33:50Z","timestamp":1733992430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924017052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":29,"alternative-id":["S0959804924017052"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115098","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liquid biopsy with plasma Epstein-Barr virus DNA characterizes biological relapse for the prediction of cancer recurrence in non-disseminated nasopharyngeal carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115098"}}